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Early diagnosis and treatment of patients with psychosis are associated with improved outcome
in terms of future functioning, symptoms and treatment response. Identifying neuroimaging
biomarkers for illness onset and treatment response would lead to immediate clinical beneﬁts.
In this review we discuss if neuroimaging may be utilised to diagnose patients with psychosis,
predict those who will develop the illness in those at high risk, and stratify patients. State-of-
the-art developments in the ﬁeld are critically examined including multicentre studies,
longitudinal designs, multimodal imaging and machine learning as well as some of the
challenges in utilising future neuroimaging biomarkers in clinical trials. As many of these
developments are already being applied in neuroimaging studies of Alzheimer's disease, we
discuss what lessons have been learned from this ﬁeld and how they may be applied to research
in psychosis.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).1. Introduction – the need for biomarkers
Despite signiﬁcant advances in our understanding of the
neurobiological basis of psychotic disorders, the assessment
of patients with psychosis is still entirely based on a clinical
interview, as it was when these disorders were ﬁrst
described over a century ago.o.2014.07.006
hed by Elsevier B.V. This is an op
/by/3.0/).
ent of Neuroimaging, PO89,
London, De Crespigny Park,
kcl.ac.uk (M.J. Kempton).Patients with psychotic disorders such as schizophrenia
usually experience prodromal symptoms 1 to 5 years prior to
the ﬁrst episode of frank psychotic illness (Hafner, 2000).
This is described as an ‘at risk mental state’ (ARMS), as
these individuals have a very high risk of developing
psychosis, but only about 30% will go on to develop the
illness (Fusar-Poli et al., 2012). There is evidence that
clinical intervention at this stage may prevent them from
developing psychosis (McGorry et al., 2002). However the
key problem in the clinical management of ARMS subjects is
that it is not possible, on the basis of clinical assessment, to
reliably predict which individuals will subsequently develop
psychosis. As a result, potentially preventative treatmentsen access article under the CC BY license
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subgroup that is destined to become psychotic. This is
clinically inefﬁcient and raises ethical concerns, as treat-
ment may be given to subjects who would not have become
psychotic in the absence of intervention. A biomarker that
could identify the subgroup that will develop psychosis
would enable preventative treatment to be targeted to
those who needed it most.
The mainstay of treatment once a psychotic disorder has
developed is antipsychotic medication. However, antipsy-
chotic medication is ineffective in about a third of psychotic
patients. The response in a given patient is unpredictable,
and can only be determined through a lengthy process of
trial and error, with the sequential evaluation of different
drugs. A neuroimaging biomarker for treatment response
might allow the unresponsive subgroup to be identiﬁed at
presentation. They could then be offered clozapine, the
only treatment that is effective in treatment resistant
patients (Kane et al., 1988).2. The search for imaging biomarkers
2.1. Multicentre studies
To identify robust neuroimaging biomarkers in psychosis for
early diagnosis and patient stratiﬁcation it is essential that
neuroimaging studies are sufﬁciently powered. However, to
date, sample size in neuroimaging studies of psychosis has been
relatively small. For example in a recent meta-analysis of 283
structural MRI studies of patients with schizophrenia (Haijma
et al., 2012), the mean sample size was 29 patients and 29
controls. However the largest effect size observed was d=0.5
to 0.6 (corresponding to the third ventricle, superior temporal
gyrus, hippocampus, and fusiform gyrus volume). From the
effect size one can calculate that to be sufﬁciently powered, a
study would need to recruit at least 45 patients and 45 controls,
which is more than 50% greater than the mean sample size.
Thus the majority of structural neuroimaging studies of schizo-
phrenia in the literature may not have been adequately
powered. A lack of power is also an issue in imaging studies
in other psychotic disorders such as bipolar disorder (Kempton
et al., 2008), and is likely to apply to fMRI and DTI studies in
psychosis, as these typically have smaller sample sizes than
structural MRI studies (Minzenberg et al., 2009). It is important
to clarify that the need for larger samples in neuroimaging
studies does not preclude the possibility that information with
clinical utility could be gleaned from a single subject (see
machine learning section below). Schizophrenia is a hetero-
geneous illness that may encompass a number of different
disorders each requiring a different approach to treatment.
Acquiring large samples will be required to identify these
subgroups. An analogous example is the successful stratiﬁcation
of different types of cancer, made possible by studying large
groups of patients. The principle biomarkers for stratiﬁcation
are the morphology of cancer cells, genetic makeup of the
cancer and particular proteins (Xing et al., 2005). In schizo-
phrenia the successful stratiﬁcation of the illness is likely to rely
on biomarkers including genetics, neuroimaging and perfor-
mance in neurocognitive tasks.
Increasing sample sizes in neuroimaging studies may be
achieved by collecting data at multiple sites. This alsoensures that identiﬁed biomarkers are determined from a
representative patient population and are not speciﬁc to a
local sample. This approach has been employed in the study
of Alzheimer's disease by the Alzheimer's disease Neuroima-
ging Initiative (ADNI), which comprises 47 sites in USA and
Canada (Jack et al., 2008). A challenge to multicentre MRI
studies is between-centre heterogeneity in the acquisition
of MRI data, which can lead to variations in estimated brain
volumes. For example, we found a between-sequence
variation of 4% in total grey matter volume (six T1 weighted
MRI sequences described in (Kempton et al., 2011)). This
amount is equal to the 4% reduction of total grey matter
volume observed in the above meta-analysis of schizophre-
nia patients compared to healthy controls (Haijma et al.,
2012). Thus if between centre/sequence heterogeneity is
not minimised this can obscure reductions in brain volume
observed in these patients. To address between centre
heterogeneity the ADNI consortium developed a structural
MRI sequence which produces an image with similar proper-
ties in terms of contrast, signal to noise ratio, and voxel
size, independent of scanner model and manufacturer. The
implementation of the ADNI MRI sequence has enabled the
pooling of imaging data across sites, and the completion of
an imaging study of Alzheimer's disease on a much larger
scale (Schuff et al., 2009) than would have been possible at
a single centre. In turn this has led to the identiﬁcation and
validation of structural neuroimaging biomarkers in Alzhei-
mer's disease and their relationship to clinical outcome
(Vemuri et al., 2009). There are additional challenges to
multi-centre studies using functional MRI, as well as match-
ing scanning parameters to obtain comparable sensitivity to
brain activation, the presentation of stimuli (including
considerations of language in international studies), record-
ing participant's responses, and minimising head movement,
all need to be standardised between centres.
In recent years, a number of prospective multicentre
imaging studies have been initiated in psychosis research.
The NAPLS study (North American Prodrome Longitudinal
Study) (Cannon et al., 2008) and EU-GEI (European network
of national schizophrenia networks studying gene-
environment interaction) (van Os et al., 2008) both include
multicentre neuroimaging of those at risk of developing
psychosis. EU-GEI is collecting clinical, genetic and environ-
mental data as well as ADNI structural MRI scans from
individuals with an at risk mental state (ARMS). The ARMS
study includes 11 centres in Europe, Australia and South
America. As ARMS subjects are relatively difﬁcult to recruit,
and there are still only a limited number of specialist clinics
globally which are able to recruit these individuals, multi-
centre studies provide an attractive way of signiﬁcantly
increasing sample size.2.2. Longitudinal neuroimaging studies
Neuroimaging biomarkers identiﬁed in cross-sectional studies
may be dependent on the stage of illness and modiﬁed by
treatment; longitudinal studies are required to examine these
effects in more detail. In this context, longitudinal designs are
more powerful than cross-sectional studies, as each subject is
effectively acts as their own control, removing variance due to
baseline differences (typically large compared to changes seen
Table 1 Advantages and disadvantages of multicentre
and longitudinal imaging studies.
Multicentre studies Longitudinal studies
Advantages Increased sample
size from pooling
data from centres,
allowing smaller
effect sizes to be
detected
More powerful
design for detecting
within subject
changes
Multicentre studies
bring together
expertise of data
collection and
analysis
Each subject acts as
its own control
which increases
sensitivity
Sample is more
representative of
the global patient
population
Required to
examine the effects
of treatment and
changes before and
after psychosis
onset
Disadvantages Increased
heterogeneity from
variations in image
acquisition, and
patient population
between centres
Participant attrition
is a signiﬁcant
challenge
particularly in
imaging studies
Variation in data
quality from
different sites
Upgrades in scanner
software and
hardware may
change image
contrast over the
lifetime of the
project
Challenges in
ensuring all
investigators are
sufﬁciently
acknowledged in
the work
Changes in research
staff may lead to
variations in the
quality of data
collection
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psychosis may be able to identify novel biomarkers associated
with the onset of psychotic illness as neuroimaging data may
be acquired before and after psychosis occurs. Multiple scans
over time also inform the continuing debate in the literature
regarding the signiﬁcance of progressive changes in brain
structure (Kempton et al., 2010; Olabi et al., 2011) and
whether these relate to the neuropathology of the disorder
(Jarskog et al., 2005), antipsychotic treatment (Ho et al.,
2011), or substance and alcohol abuse (Welch et al., 2011).
There are particular challenges in conducting a longitudinal
study, including sample attrition, upgrades of scanner hard-
ware and software during the study, and even changes in the
research staff running the project. Sample attrition rates
depend on the length of follow-up, characteristics of the
patient population and the research staff, and participants'
opinions of the research project after their baseline assess-
ment. Attrition rates are not always published; however rates
up to 50% have been reported in longitudinal MRI studies of
patients with psychosis (Thompson et al., 2009). Subject
attrition leads to a reduction in statistical power due to
reduced sample size. However a more serious problem is
attrition bias, for example, if poorer functioning patients are
less likely to attend follow-up, this will lead to an unrepre-
sentative follow-up group. Therefore attrition should be
minimised, and participants who do not attend follow-up
should be compared to the included sample in terms of
clinical and demographic characteristics. Neuroimaging scan-
ners in research centres may have regular software and
hardware upgrades which may have subtle effects on image
contrast and geometric distortion. When processed with image
analysis software this may lead to changes in regional brain
volume, fMRI activation strength and differences in other
modalities. Even changes in staff at the neuroimaging centre
over time may lead to subtle effects, such as how the subject
is positioned in the scanner. Although in a long term study
scanner upgrades and staff changes may be unavoidable, it is
important that there is no systematic difference between the
patient and control group in regard to these changes. Long-
itudinal studies may provide better predictors of clinical
outcomes in psychosis than a single scan. For example,
(Cahn et al., 2006) found that the longitudinal change in MRI
measures in the ﬁrst year after the onset of psychosis
predicted long term functional outcome, whereas the MRI
data at baseline alone did not. However, the potential beneﬁts
of serial scanning have to be weighed against the increased
logistical demands of longitudinal imaging studies, which may
impact on the feasibility of the assessment in a clinical setting.
Although longitudinal studies are known to be more powerful
for detecting within subject change, it is unclear what
difference this makes in terms of the required sample size
for neuroimaging studies in psychosis. Therefore we investi-
gated the example of detecting progressive changes (volume
change greater than aging) in the volume of the lateral
ventricles in patients with schizophrenia in a longitudinal
versus cross-sectional design. In a longitudinal study this could
be achieved by scanning patients and controls at baseline and
at follow-up. In a cross-sectional study this could be deter-
mined by measuring the correlation between duration of
illness and ventricle volume among patients. To calculate
the required sample size to detect a signiﬁcant effect, we
conducted a numerical simulation where participants wereassigned random demographic and clinical values from dis-
tributions matching typical imaging studies (mean age at
baseline=2976 years, duration of illness at baseline=774
years, follow-up period=3.5 years, (Kempton et al., 2010)).
The effects of demographic and clinical variables on lateral
ventricle volume were linearly modelled based on data
published in previous studies (Haijma et al., 2012; Kempton
et al., 2010; Kempton et al., 2011). From the simulation, we
determined that a longitudinal study would require 64 patients
and 64 controls to be sufﬁciently powered to detect progres-
sive changes. In contrast a cross-sectional study would require
1260 patients for sufﬁcient power to detect a correlation
between ventricular volume and duration of illness. In this
example a longitudinal design would be much more efﬁcient
because of large inter-subject variability in baseline ventri-
cular volume and the relatively small effect of illness dura-
tion. The advantages and disadvantages of multicentre and
longitudinal imaging studies are summarised in Table 1.
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neuroimaging data
Choosing the most suitable antipsychotic for a patient with
ﬁrst episode psychosis is often a process of trial and error.
Ideally a clinician would be able to choose the best suited
antipsychotic for a particular patient on the basis of
investigations, without the need to evaluate a series of
drugs over a lengthy period. A promising area of research is
using neuroimaging assessments, prior to treatment to
predict the response to antipsychotics. Kapur et al. (2000)
demonstrated with PET (Positron Emission Tomography) that
clinical response correlated with D2 receptor occupancy but
that high occupancy 472% was associated with extrapyr-
amidal side effects. Arango et al. (2003) reported that
patients with higher regional brain volumes were more
likely to beneﬁt from clozapine treatment, and more at
risk of side effects when treated with haloperidol. In a more
recent study, Demjaha et al. (2012) found that patients who
were responsive to antipsychotics had increased dopamine
synthesis compared to both healthy controls and patients
with treatment resistant schizophrenia. Using MR spectro-
scopy, Egerton et al. (2012) found that a poor response to
antipsychotic medication in ﬁrst episode patients was
associated with elevated glutamate levels in the anterior
cingulate cortex. Demjaha and Egerton had initially
reported on separate samples but in a new publication
(Demjaha et al., 2014) they assessed the same patient
sample with both PET and MRS and reported that elevated
glutamate levels within the anterior cingulate and normal
presynaptic dopamine synthesis were both features of poor
response to antipsychotic medication. The abnormalities
identiﬁed by Demjaha et al. (2014) are biologically plausible
as existing antipsychotics block the D2 receptor while the
glutamate system is a proposed target for novel antipsycho-
tics (Conn et al., 2009). Recent research has also used
neuroimaging measures to predict the response to psycho-
logical therapies. Premkumar et al. (2009) reported that the
response to cognitive behavioural therapy in patients with
psychosis was associated with regional differences in grey
matter volume, with an improvement in positive symptoms
correlated with increased right cerebellar volume.
Ideally, when assessing whether neuroimaging measures
can predict treatment response, neuroleptic naive patients
should be recruited. This is particularly important, as there
is increasing evidence that antipsychotic use may be
associated with changes in grey matter volume over time
(Ho et al., 2011), as well as with changes in regional brain
function (Handley et al., 2013). However antipsychotic
naive patients are difﬁcult to recruit, and the majority of
imaging studies in psychosis have included medicated
patients. The OPTiMiSE study (Optimization of Treatment
and Management of Schizophrenia in Europe, www.optimi
setrial.eu) is a prospective multicentre clinical trial to
optimise treatment in medication naive patients with
schizophrenia. In this study, patients with ﬁrst episode
psychosis have an MRI scan at baseline and then start
treatment with amisulpride. Patients with a poor response
after 4 weeks are randomised to continuation on amisulpride
or a switch to olanzapine. If patients continue to have
psychotic symptoms they are offered clozapine. The OPTiMiSEtrial uses the ADNI MRI protocol, ensuring that neuroimaging
data can be pooled among the participating centres. The
study will thus be able to examine the extent to which
neuroimaging data can be used to predict antipsychotic
response.
When assessing the contribution of neuroimaging, it is
also informative to examine if other biomarkers or clinical
variables have been successful in predicting treatment
response. In relation to genetics, Zhang et al. (2010)
reported in a meta-analysis that a polymorphism present
in the gene that encodes the dopamine D2 receptor was
associated with a signiﬁcant change in clinical response to
antipsychotics, while genome wide association studies
(GWAS) which survey the entire genome have begun to
report associations with antipsychotic response (McClay
et al., 2011), see also review by Arranz and de Leon
(2007). In terms of clinical variables, a meta-analysis by
Perkins et al. (2005) demonstrated that a shorter duration
of untreated psychosis was associated with an improved
response to antipsychotics, while Crespo-Facorro et al.
(2007) reported that an earlier age of onset predicted a
poor response. Finally in a sample of 263 patients Green
et al. (2004) found that patients with co-occurring sub-
stance abuse were less likely to respond when treated with
either olanzapine or haloperidol. Thus neuroimaging may be
one of a number of measures that can inform the prediction
of response to speciﬁc antipsychotics.2.4. Multimodal imaging
Multimodal imaging allows for one to investigate brain dysfunc-
tion using a range of measurement techniques within the same
individual. Imaging in more than one modality (structural MRI,
PET, fMRI, DTI, etc.) in the same patient may reveal detail
about the neuropathophysiology of psychosis which could not be
elucidated by one type of imaging alone. Multimodal imaging
has also been successfully applied in Alzheimer's disease;
structural MRI reveals prominent volumetric reductions in the
hippocampus, PET scans with FDG (an analogue of glucose)
show reduced metabolism, and PETscans with a ligand sensitive
to beta-amyloids plagues (Pittsburgh compound B, PiB) reveal
the distribution of this peptide in the brain (Jack et al., 2009).
Multimodal imaging studies in patients with psychosis are most
commonly MRI based techniques, as the subject can be scanned
with a variety of sequences on the same scanner during a single
session. However a limited number of centres which have
access to both MRI and PET based scannings have been able to
combine these data. Kalus et al. (2005) used 3 modalities
namely structural MRI, diffusion tensor imaging (DTI) and
magnetisation transfer imaging (MTI) to investigate the struc-
ture of the amygdala in patients with schizophrenia compared
to healthy controls. Although no change in volume was found,
diffusional anisotropy measured by DTI was reduced in patients
and MTI parameters showed signiﬁcant group differences. The
latter two results may indicate abnormalities of intra-
amygdaloid ﬁbres and a reduction in white to grey matter ratio
within the amygdala. Fusar-Poli et al. (2010) combined fMRI and
PET datasets which measured brain activation in a working
memory task, and dopamine synthesis, respectively. Data was
acquired from 20 subjects with an at risk mental state
compared to 14 healthy controls. The authors reported
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and activation in the prefrontal cortex among ARMS partici-
pants. In a recent study, Smieskova et al. (2012) combined
structural MRI data with fMRI data in a group of patients with
ﬁrst episode psychosis, ARMS and controls. This study used a
technique known as biological parametric mapping (Casanova
et al., 2007), which allows voxelwise analysis of multimodal
imaging data. Activation during a working memory task was
reduced in a subgroup of ARMS subjects in the insular and
prefrontal cortex which co-localised with a reduction in grey
volume in the same regions. Sui et al. (2012) developed an
alternative technique using canonical correlational analysis
(CCA) and joint independent component analysis (ICA), to
combine data from structural MRI, fMRI, and DTI scans. The
methodology was applied to a large group of schizophrenia
patients (n=97) and healthy controls (n=116) who had all been
scanned using the 3 imaging modalities. Components discrimi-
nating patients and controls were found across the modalities,
and a subgroup of components correlated with duration of
illness. As the above selection of studies show there are a
number of different combinations of imaging modalities and
methodologies by which these data may be combined, making
it challenging to summarise the ﬁndings from these studies. It is
therefore encouraging that a method has been speciﬁcally
developed to meta-analyse multimodal data. Radua et al.
(2012) has developed a multimodal voxel-wise meta-analysis
technique which has been applied to structural and functional
MRI studies in patients with ﬁrst episode psychosis. The
technique allows the inclusion of independent fMRI and MRI
studies meaning the meta-analysis is not restricted to studies
which used a multimodal approach. The meta-analysis by Radua
et al. identiﬁed both functional and structural abnormalities in
the insula, superior temporal gyrus, medial frontal cortex and
anterior cingulate. The meta-analyses also allowed the inves-
tigation of between study heterogeneity and by using meta-
regression techniques determined that antipsychotic use was
associated with structural abnormalities of the anterior cingu-
late and left insula.
Multimodal imaging may be an effective way of applying
patient stratiﬁcation prior to future clinical trials due to
increased power to characterise subgroups from complemen-
tary measures. For example as reported above Demjaha et al.
(2014) found that patients with elevated anterior cingulate
glutamate levels (measured with MRS) and normal presynaptic
dopamine synthesis (determined with PET) will have a poor
response to antipsychotic medication. Thus prior to a clinical
trial these patients could be identiﬁed and either excluded or
treated with an adjunct medication. Using two other imaging
modalities, namely structural MRI and electroencephalography
(EEG), Molina et al. (2008) had shown that treatment resistance
was associated with reduced frontal grey matter volume and a
reduction in the intensity of the EEG P300 amplitude.2.5. Machine learning approaches to classify
individual patients
Research is often concerned with large groups of patients, while
in the clinic decisions need to made based on information from
a single patient. The requirement of large sample sizes referred
to in the section above regarding multicentre studies may
indicate that being able to apply this research to a singlepatient is not possible. However new approaches from the ﬁeld
of machine learning are increasingly being applied to neuroima-
ging data with an ability to classify a patient in terms of
diagnosis based on their MRI data alone. The machine learning
algorithm is presented with a training set of neuroimaging data
in which the images are labelled by diagnosis, and after the
training step the algorithm is able to classify entirely new
neuroimaging data by diagnosis. The application of machine
learning approaches in neuroimaging parallels an increase in the
use of this tool, which is currently being applied to diverse
datasets within medicine, such as the classiﬁcation of survival
rates in cancer from RNA expression (Olmos et al., 2012),
identiﬁcation of active tuberculosis from serum proteins
(Agranoff et al., 2006) and the subdivisions of ADHD from
neuropsychological data (Fair et al., 2012). A full technical
description is beyond the scope of this paper; however the
theory of machine learning and its application to neuroimaging
is discussed in detail in two recent reviews (Kloppel et al.,
2012; Orru et al., 2012). As machine learning approaches are a
multivariate technique, the classiﬁcation is not only based on
regional differences in brain volume/activation, but also
depends on covariance between brain regions. These techni-
ques have recently been applied to neuroimaging in psychosis.
Koutsouleris et al. (2009) used multivariate pattern classiﬁca-
tion of structural MRI data to successfully classify those with an
at risk mental state and healthy controls. Furthermore based on
the scans acquired at baseline they were able to use the
technique to predict who would transition to psychosis com-
pared to non-transitions and healthy controls with an accuracy
of 88%. A method of pattern classiﬁcation known as support
vector machines (SVM) was applied to spectro-temporal data
recorded using magnetoencephalography (MEG) by Ince et al.
(2008). The authors reported 92% accuracy in classifying
patients with schizophrenia compared to controls. The most
discriminant signals used in the classiﬁcation were located on
the left side of the brain in the alpha, theta and delta
frequency bands. Yoon et al. (2007) also used SVM but applied
this to cortical thickness measures from structural MRI data.
The accuracy of classiﬁcation of patients with schizophrenia
compared to healthy controls was at a similar level to the
previous studies with an accuracy of 88–94% depending on the
cortical lobe entered into the analysis. Costafreda et al. (2011)
applied SVM classiﬁcation to fMRI data of a verbal ﬂuency task
to distinguish patients with schizophrenia, bipolar disorder and
healthy controls. Interesting although the SVM algorithm was
successful at distinguishing patients with schizophrenia with an
accuracy of 92%, the accuracy in identifying patients with
bipolar disorder was lower with a number of these patients
being misclassiﬁed as controls. In summary, machine learning
approaches have shown promising results in determining psy-
chiatric diagnosis from neuroimaging data. The highest accura-
cies in classiﬁcation are around 90%, however this would need
to substantially increase to be clinically useful. Conversely
there has been some sceptiscm regarding the high levels of
classiﬁcation accuracy in neuroimaging studies, especially as
recent DSM-5 ﬁeld trials have reported a wide range of
reliability for psychiatric diagnoses (Regier et al., 2013). The
reliability for schizophrenia diagnosis was judged as ‘good’ with
an associated kappa=0.46. As the training stage of machine
learning depends on human diagnosis it may therefore be
surprising that these algorithms are able to classify patents
with an accuracy of 90%. However it should be noted that the
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word clinic rather than a research institution, and clinicians did
not use the Structured Clinical Interview for DSM (SCID) which is
known to improve the reliability of diagnosis (e.g. kappa=0.65
for DSM-III-R schizophrenia) (Williams et al., 1992). Most of the
imaging examples above compared patients with schizophrenia
to healthy controls, however a more clinically useful test would
be used to determine the diagnosis of a patient who was
difﬁcult to classify based on symptoms, for example determin-
ing if a patient with psychosis had bipolar disorder or schizo-
phrenia. It is possible that adding other types of data to the
machine learning algorithm such as neuropsychological, genetic
and demographic information may lead to improved accuracy.2.6. Translational neuroimaging: considerations of
cost and regulatory approval of neuroimaging
biomarkers
In terms of translating neuroimaging ﬁndings from the research
arena to the clinic, it is important to consider the cost, image
acquisition time, availability of imaging techniques in hospitals,
and the skills needed to process and interpret data. For
example PET imaging has been used with speciﬁc ligands to
measure dopamine receptor availability in patients with schizo-
phrenia (Howes et al., 2011) and amyloid plaques in patients
with Alzheimer's disease (Jack et al., 2009). However these
types of PET scans cost several thousand of Euros per patient,
which may make it prohibitively expensive to use as a clinical
tool. Diffusion tensor imaging has identiﬁed abnormalities in
white matter tracts in patients with schizophrenia (Kanaan
et al., 2009). However, at present the acquisition time and MRI
hardware required mean that it is not easy for this technique to
be adopted in some clinical centres. Structural MRI has an
advantage as these types of images are routinely collected in
hospitals. The post-processing of the images is complex but it is
conceivable that an automated analysis pipeline can be devel-
oped and with the continuing rise in computing power, results
would be available in a comparable time to having the image
examined by a radiologist, but with the advantage that the
results would be quantitative, standardised and not susceptible
to inter-rater variability. If research demonstrated a robust
neuroimaging biomarker for diagnosis or treatment response for
patients with psychosis, a number of regulatory approvals
would be needed before utilising the biomarker in clinical trials
and in clinical diagnosis. No neuroimaging biomarker has
reached this stage in psychosis research, but in Alzheimer's
disease, automatic quantiﬁcation of hippocampal volume is
currently being considered for clinical trials (Jack et al., 2011).
Approval by regulatory bodies such as the US Food and Drug
Administration (FDA) and European Medicines Agency (EMA)
would require comprehensive step-by-step validation and
documentation of the technique (including the scanning
protocol, data preprocessing and statistical analysis). Cur-
rently popular neuroimaging packages expressly advise
against clinical applications in their software licence agree-
ments (see http://surfer.nmr.mgh.harvard.edu). In terms of
looking forward, developers of neuroimaging software
should consider that their algorithms may need to be
adapted in the future for clinical applications and to
document and validate processing steps in preparation for
this. As both clinical trials and fulﬁlling regulatory approvalare costly, it is important to foster links with industrial
partners who would be able invest in the development of
neuroimaging biomarkers (e.g. IXICO; www.ixico.com).
2.7. Translational neuroimaging in 2025
In this paper we have reviewed progress in the ﬁeld of
translational neuroimaging in psychosis; however how will
the ﬁeld look 10 years from now? We would like to see
increased standardisation of MRI sequences allowing data
from different centres and scanners to be easily combined
which would be used in both multicentre and longitudinal
studies. This would lead to the development of large public
repositories of standardized MRI data of patients with
psychosis paired with detailed demographic and clinical
data. Access to these repositories would allow machine
learning algorithms to be ﬁne-tuned to predict treatment
response and illness course in a subpopulation of patients. In
parallel to the developments in neuroimaging, there is the
hope that full genome sequencing in over half a million
patients with schizophrenia will have identiﬁed hundreds of
thousands of SNPs where each contribute to small effect of
developing psychosis. Algorithms using polygenic scores
could then be used to calculate psychosis risk for individuals
as well as specifying which environmental factors should be
avoided (such as cannabis use). For those identiﬁed as
having a high risk of developing psychosis, regular MRI
scans, proteomic analysis, clinical interviews and cognitive
testing could be provided to monitor changes that might
suggest the onset of a psychotic illness.
3. Conclusion
Neuroimaging research in psychosis has substantially
advanced our understanding of the pathophysiology of the
disorder. The challenge currently facing neuroimaging in
this ﬁeld is to translate these ﬁndings into mainstream
clinical practice. The use of large scale multi-centre studies
using standardised protocols, multi-modal imaging, the
application of new analytical approaches like machine
learning, and relating imaging measures to clinically mean-
ingful outcomes will facilitate work towards this goal.
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